Compare Alcon AG (ALC) vs Alibaba Group (BABA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Alibaba Group — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Alibaba Group trades at $109.39 (market cap $234.34B). The key difference: Alibaba Group is far larger — about 7.2× Alcon AG's market cap, and Alibaba Group pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| ALC | BABA | |
|---|---|---|
Market Cap | $32.69B | $234.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $189.34 |
52-Week Low | $62.02 | $94.83 |
Enterprise Value | $36.28B | $229.16B |
Dividend Yield | 0.54% | 1.07% |
Volume | — | 18,069,938 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Alibaba (BABA) trades at $98.14, up 2.08% today, but remains in a bearish technical trend with recent earnings misses. The company reported strong revenue growth to $996.35B in 2025 and a net income margin of 13.05%, yet faces headwinds from regulatory investigations and a $600M DOJ settlement. Analyst consensus is overwhelmingly bullish with an $195 price target, highlighting a significant discount to intrinsic value despite near-term challenges.
The stock presents a contrarian opportunity with attractive valuations (P/E 15.13, P/S 1.56) amid pessimism. Key risks include ongoing legal probes, AI competition, and macroeconomic pressures. Upside depends on earnings recovery and resolution of regulatory overhangs, making it a high-risk, high-reward play for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
